Innoviva, Inc.INVA stock score: 63/100
$18.41 · +0.05% · Scored Nov 19, 2026
- Technical
- 40
- Fundamental
- 69
- News
- 56
The reading
Innoviva (INVA) scores 63 out of 100, which reads neutral, higher than 86% of Healthcare stocks and 87% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 69, technicals 40.
Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Earnings Growth (Quarterly) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 17 and contrarian oscillators 78 — a split worth reading before trusting the technical total.
News sentiment is neutral at 56; it is shown, not counted in the composite.
Since Aug 23, 2026 the composite has ranged from 54 to 65, and it is up 1 point over the period.
About Innoviva
Innoviva (INVA) is a diversified healthcare company that owns royalty interests, sells hospital medicines and holds stakes in other healthcare companies. Its royalty business receives payments from GSK on global sales of the respiratory medicines RELVAR/BREO ELLIPTA and ANORO ELLIPTA, which treat asthma and chronic obstructive pulmonary disease. Its specialty therapeutics business, Innoviva Specialty Therapeutics, sells critical care and infectious disease drugs to hospitals, including GIAPREZA for septic shock and other forms of low blood pressure, XACDURO for serious Acinetobacter infections and XERAVA for complicated abdominal infections, and it also holds the oral gonorrhea treatment zoliflodacin. It works with partners to sell some products outside the United States. Innoviva also holds strategic investments in healthcare companies, including a large stake in Armata Pharmaceuticals. It earns money from royalties, product sales and, at times, gains on investments.
Innoviva’s respiratory royalties depend on GSK’s competition with AstraZeneca, Boehringer Ingelheim and generic inhalers, while its hospital drugs compete with products from Merck, Pfizer and Shionogi and with older generic treatments. Its edge rests on steady royalty cash flow that funds growth in specialty products and a portfolio of drugs for hard-to-treat hospital infections. Investors who follow INVA stock tend to watch sales growth of GIAPREZA and XACDURO. GSK royalty trends and the launch of zoliflodacin are closely followed. The value of strategic investments, convertible debt and share buybacks are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward INVA’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
69Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Holding it back
Net income growth against the same quarter a year earlier, weighted toward the latest quarter.
5-year earnings growth evaluates long-term profit trajectory and consistency.
Earnings estimates score evaluates analyst projections for future profitability.
38 weighted scorers; 1 had no data today and are left out rather than counted as zero.
Technical · daily
26Pulling it up
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
- RSI (14)99
Relative Strength Index (14-period) measures momentum by comparing recent gains to losses.
Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.
Holding it back
Where the price sits between its 52-week low and high.
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
- VWAP0
Volume Weighted Average Price (VWAP) shows the average price weighted by volume.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 56
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 46 | 1 |
| Daily | 26 | 3 |
| Weekly | 32 | 2 |
| Monthly | 54 | 2 |
| Quarterly | 53 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 63 |
| Nov 18, 2026 | 63 |
| Nov 17, 2026 | 63 |
| Nov 16, 2026 | 63 |
| Nov 15, 2026 | 64 |
| Nov 14, 2026 | 64 |
| Nov 13, 2026 | 64 |
| Nov 12, 2026 | 64 |
| Nov 11, 2026 | 54 |
| Nov 10, 2026 | 56 |
| Nov 8, 2026 | 54 |
| Nov 7, 2026 | 54 |
| Nov 6, 2026 | 54 |
| Nov 5, 2026 | 56 |
| Nov 4, 2026 | 62 |
| Nov 3, 2026 | 62 |
| Nov 2, 2026 | 64 |
| Nov 1, 2026 | 64 |
| Oct 30, 2026 | 64 |
| Oct 29, 2026 | 65 |
| Oct 28, 2026 | 63 |
| Oct 27, 2026 | 62 |
| Oct 26, 2026 | 62 |
| Oct 25, 2026 | 60 |
| Oct 24, 2026 | 60 |
| Oct 23, 2026 | 60 |
| Oct 22, 2026 | 62 |
| Oct 21, 2026 | 64 |
| Oct 20, 2026 | 65 |
| Oct 19, 2026 | 62 |
| Oct 18, 2026 | 61 |
| Oct 17, 2026 | 61 |
| Oct 16, 2026 | 61 |
| Oct 15, 2026 | 62 |
| Oct 14, 2026 | 62 |
| Oct 13, 2026 | 62 |
| Oct 12, 2026 | 65 |
| Oct 11, 2026 | 64 |
| Oct 10, 2026 | 64 |
| Oct 9, 2026 | 64 |
| Oct 8, 2026 | 63 |
| Oct 7, 2026 | 63 |
| Oct 6, 2026 | 61 |
| Oct 5, 2026 | 60 |
| Oct 4, 2026 | 59 |
| Oct 3, 2026 | 59 |
| Oct 2, 2026 | 59 |
| Oct 1, 2026 | 61 |
| Sep 30, 2026 | 64 |
| Sep 29, 2026 | 63 |
| Sep 28, 2026 | 62 |
| Sep 27, 2026 | 60 |
| Sep 26, 2026 | 61 |
| Sep 25, 2026 | 61 |
| Sep 24, 2026 | 62 |
| Sep 23, 2026 | 62 |
| Sep 22, 2026 | 63 |
| Sep 21, 2026 | 63 |
| Sep 20, 2026 | 63 |
| Sep 19, 2026 | 63 |
| Sep 18, 2026 | 64 |
| Sep 17, 2026 | 63 |
| Sep 16, 2026 | 64 |
| Sep 15, 2026 | 62 |
| Sep 14, 2026 | 62 |
| Sep 13, 2026 | 61 |
| Sep 12, 2026 | 61 |
| Sep 11, 2026 | 61 |
| Sep 10, 2026 | 61 |
| Sep 9, 2026 | 62 |
| Sep 8, 2026 | 64 |
| Sep 7, 2026 | 63 |
| Sep 6, 2026 | 63 |
| Sep 5, 2026 | 64 |
| Sep 4, 2026 | 64 |
| Sep 3, 2026 | 63 |
| Sep 2, 2026 | 65 |
| Sep 1, 2026 | 63 |
| Aug 31, 2026 | 61 |
| Aug 30, 2026 | 61 |
| Aug 29, 2026 | 61 |
| Aug 28, 2026 | 61 |
| Aug 27, 2026 | 61 |
| Aug 26, 2026 | 64 |
| Aug 25, 2026 | 63 |
| Aug 24, 2026 | 62 |
| Aug 23, 2026 | 62 |
Key facts
- Market cap
- $1.3B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 0.37
- Risk grade (1–10)
- 6
- Next earnings
- Nov 4, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| NUVB Nuvation Bio | $1.3B | 40 |
| NTLA Intellia Therapeutics | $1.3B | 33 |
| LBRX LB Pharmaceuticals | $1.3B | 41 |
| OCUL Ocular Therapeutix | $1.3B | 38 |
| GHRS GH Research | $1.3B | 42 |
| NVAX Novavax | $1.3B | 55 |
Questions
What is INVA's stock rating today?
INVA scores 63/100 (Neutral) as of Nov 19, 2026: technical 40, fundamental 69, and news sentiment 56, which is shown but not counted. Scores are recomputed every night.
What does Innoviva do?
Innoviva (INVA) is a diversified healthcare company that owns royalty interests, sells hospital medicines and holds stakes in other healthcare companies. Its royalty business receives payments from GSK on global sales of the respiratory medicines RELVAR/BREO ELLIPTA and ANORO ELLIPTA, which treat asthma and chronic obstructive pulmonary disease.
Is INVA stock a buy?
The score is not a buy or sell recommendation. A 63 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the INVA score calculated?
100 weighted scorers feed it today: 38 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 5 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/inva/"><img src="https://stocksscores.com/stocks/inva/badge.svg" alt="INVA stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/inva/)